CA2366723A1 - Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes - Google Patents

Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes Download PDF

Info

Publication number
CA2366723A1
CA2366723A1 CA002366723A CA2366723A CA2366723A1 CA 2366723 A1 CA2366723 A1 CA 2366723A1 CA 002366723 A CA002366723 A CA 002366723A CA 2366723 A CA2366723 A CA 2366723A CA 2366723 A1 CA2366723 A1 CA 2366723A1
Authority
CA
Canada
Prior art keywords
fatty acid
acid
taxane
anticancer compound
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002366723A
Other languages
English (en)
Other versions
CA2366723C (fr
Inventor
Nigel L. Webb
Matthews O. Bradley
Forrest Anthony
Mark Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Regent Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/265,307 external-priority patent/US7235583B1/en
Application filed by Individual filed Critical Individual
Publication of CA2366723A1 publication Critical patent/CA2366723A1/fr
Application granted granted Critical
Publication of CA2366723C publication Critical patent/CA2366723C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des conjugués d'acides gras et d'agents anticancéreux utilisés dans le traitement du cancer, ainsi que des compositions et des formulations renfermant ces conjugués. L'invention concerne également des méthodes d'utilisation desdits conjugués.
CA2366723A 1999-03-09 2000-03-09 Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes Expired - Fee Related CA2366723C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/265,307 1999-03-09
US09/265,307 US7235583B1 (en) 1999-03-09 1999-03-09 Fatty acid-anticancer conjugates and uses thereof
US18615200P 2000-03-01 2000-03-01
US60/186,152 2000-03-01
PCT/US2000/006160 WO2000053231A2 (fr) 1999-03-09 2000-03-09 Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes

Publications (2)

Publication Number Publication Date
CA2366723A1 true CA2366723A1 (fr) 2000-09-14
CA2366723C CA2366723C (fr) 2011-08-02

Family

ID=26881822

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2366723A Expired - Fee Related CA2366723C (fr) 1999-03-09 2000-03-09 Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes

Country Status (10)

Country Link
EP (1) EP1163011A2 (fr)
JP (1) JP2002538224A (fr)
KR (1) KR20020000147A (fr)
CN (1) CN1377282A (fr)
AU (1) AU3733300A (fr)
CA (1) CA2366723C (fr)
CZ (1) CZ20013123A3 (fr)
HK (1) HK1040486A1 (fr)
RU (1) RU2001127313A (fr)
WO (1) WO2000053231A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US7816398B2 (en) * 2001-03-23 2010-10-19 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
JP2005500988A (ja) * 2001-03-23 2005-01-13 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪族アミン薬物複合体
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
CN100341589C (zh) 2002-05-24 2007-10-10 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
CA2529125A1 (fr) 2003-06-19 2004-12-23 Yeda Research & Development Co. Ltd. Lipopeptides antimicrobiens et anticancereux
EP1703904B1 (fr) * 2003-10-30 2013-02-13 The Research Foundation of the State University of New York Conjugues taxoide/acide gras et preparations les contenant
JP4929158B2 (ja) * 2005-03-14 2012-05-09 株式会社大塚製薬工場 難水溶性薬物を含有する医薬組成物
KR100753112B1 (ko) * 2007-02-26 2007-08-29 (주)고려다이나믹스 카드 발권 시스템
AU2013288738A1 (en) * 2012-07-10 2015-01-29 Baseclick Gmbh Anandamide-modified nucleic acid molecules
CN117088935A (zh) * 2022-05-20 2023-11-21 上海维洱生物医药科技有限公司 一种雷公藤甲素木蜡酸酯及其脂质体与制备方法
KR20230174082A (ko) * 2022-06-20 2023-12-27 (주) 바이오인프라생명과학 약물을 전달하기 위한 초음파 감응형 약물전달체를 생성하는 방법 및 이를 이용한 초음파 감응형 약물전달체
CN116676355B (zh) * 2023-08-03 2023-10-24 成都第一制药有限公司 一种催化合成山莨菪碱的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925327A (ja) * 1982-07-31 1984-02-09 Hidematsu Hirai 抗腫瘍性複合体の製造方法
AU3243393A (en) * 1991-12-10 1993-07-19 Rush - Presbyterian - St. Luke's Medical Center Methods and compositions for reducing multi-drug resistance
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
JP4172726B2 (ja) * 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6136988A (en) * 1998-04-10 2000-10-24 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same

Also Published As

Publication number Publication date
RU2001127313A (ru) 2003-09-20
CZ20013123A3 (cs) 2002-03-13
AU3733300A (en) 2000-09-28
CN1377282A (zh) 2002-10-30
WO2000053231A2 (fr) 2000-09-14
JP2002538224A (ja) 2002-11-12
HK1040486A1 (zh) 2002-06-14
KR20020000147A (ko) 2002-01-04
CA2366723C (fr) 2011-08-02
WO2000053231A3 (fr) 2001-10-04
EP1163011A2 (fr) 2001-12-19

Similar Documents

Publication Publication Date Title
Hörmann et al. Drug delivery and drug targeting with parenteral lipid nanoemulsions—A review
CA2366723A1 (fr) Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes
US6720001B2 (en) Emulsion compositions for polyfunctional active ingredients
Kan et al. A liposomal formulation able to incorporate a high content of Paclitaxel and exert promising anticancer effect
US6146659A (en) Method of administering liposomal encapsulated taxane
Koudelka et al. Liposomes with high encapsulation capacity for paclitaxel: Preparation, characterisation and in vivo anticancer effect
JP2013501806A5 (fr)
RU2012109405A (ru) Композиции антагонистов нейрокинина-1 для внутривенного введения
IL113021A (en) Oil in water emulsion compositions containing edetate
KR20070059072A (ko) 알파 토코페릴 석시네이트, 이의 동족체 및 이의 염의안정한 주사용 조성물
JP2008534525A (ja) リン脂質のポリエチレングリコール誘導体に包み込まれたアンスラサイクリン系抗腫瘍抗生物質のナノミセル製剤
Cortesi et al. Liposomes, micelles and microemulsions as new delivery systems for cytotoxic alkaloids
WO2012035480A2 (fr) Compositions pharmaceutiques de curcumine
JP2008517023A (ja) アルキルホスホコリンを含有する新規の負電荷担体を使用した配合物
AU2008345527A1 (en) Novel taxoid-based compositions
US7449197B2 (en) Liposome formulation of 6,9-bis[(2-aminoethyl)-amino]benzo[g]isoquinoline-5, 10-dione dimaleate
CN100531720C (zh) 一种羟基喜树碱长循环纳米脂质载体及其制备方法
US8349894B2 (en) Compositions comprising an o/w emulsion containing conjugated linoleic acid
US20110082193A1 (en) Taxane derivative containing pharmaceutical composition with improved therapeutic efficacy
Lee et al. Stable paclitaxel formulations in oily contrast medium
CN1895262B (zh) 表阿霉素注射用乳剂及制备方法
CN1875946A (zh) 10－羟基喜树碱纳米粒及其制备方法
EP0758237A1 (fr) Formulation stable sous forme lactone de camptothecine ou 7-ethyle camptothecine
Chen Research Progress of Ascorbyl Palmitate in Drug Delivery and Cancer Therapy
CN115089720B (zh) 一种肿瘤治疗药物组合

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170309